News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Exxel Pharma presents its EX937 development program targeting refractory chronic cough, a $11B market need. Phase 1/1b study in normal volunteers starts Q3/4 2025 with unique FAAH inhibition approach -
-
COMMUNIQUÉ DE PRESSE
MicroVision Bolsters Financial Position with Debt Reduction and up to $17 Million in New Capital
MicroVision, Inc. strengthens financial position by raising $17 million in new capital and reducing debt obligations. Focus on industrial customer partnerships and automotive OEM engagements -